CV Sciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
CVSIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Product sales, net | $3,256 | $3,865 | $10,482 | $11,821 |
| Cost of goods sold | 1,677 | 2,087 | 5,401 | 6,330 |
| Gross profit | 1,579 | 1,778 | 5,081 | 5,491 |
| Operating expenses: | ||||
| Research and development | 24 | 29 | 104 | 93 |
| Selling, general and administrative | 1,830 | 2,090 | 5,894 | 6,942 |
| Benefit from reversal of accrued payroll taxes (Note 12) | — | — | (522) | — |
| Total operating expenses | 1,854 | 2,119 | 5,476 | 7,035 |
| Operating loss | (275) | (341) | (395) | (1,544) |
| Gain on extinguishment of debt | — | — | (38) | — |
| Interest expense, net | 107 | 115 | 388 | 118 |
| Loss before income taxes | (382) | (456) | (745) | (1,662) |
| Income tax expense | — | — | 7 | 6 |
| Net loss | $(382) | $(456) | $(752) | $(1,668) |
| Weighted average common shares outstanding, basic and diluted | 184,264 | 182,261 | 184,264 | 172,671 |
| Net loss per common share, basic and diluted | $(0.00) | $(0.00) | $(0.00) | $(0.01) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.